Inhibitory effect of several fluoroquinolones on hepatic microsomal cytochrome P-450 1A activities in dogs

被引:31
作者
Regmi, NL
Abd El-Aty, AM
Kuroha, M
Nakamura, M
Shimoda, M [1 ]
机构
[1] Tokyo Univ Agr & Technol, Dept Vet Med, Fac Agr, Tokyo 1838509, Japan
[2] Cairo Univ, Fac Vet Med, Dept Pharmacol, Giza, Egypt
关键词
D O I
10.1111/j.1365-2885.2005.00698.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
We examined inhibitory effects of ofloxacin (OFX), orbifloxacin (OBFX), ciprofloxacin (CFX), enrofloxacin (EFX) and norfloxacin (NFX) on cytochrome P-450 1A (CYP1A) activities using hepatic microsomes from four beagle dogs. Ethoxyresorufin O-de-ethylation was referred as CYP1A activities. All the fluoroquinolones inhibited the reaction in a noncompetitive manner. The determined inhibitory constants were the followings; 10.1 +/- 3.8 mM for OFX, 6.43 +/- 2.01 mM> for OBFX, 0.726 +/- 0.134 mM for CFX, 4.06 +/- 1.19 mM for EFX and 4.75 +/- 1.63 mM for NFX respectively. As these values are > 100-fold of plasma concentrations after a clinical single dose of the fluoroquinolones, it is suggested that the inhibitory effect on CYP1A activities is not so high to elicit drug-drug interaction with CYP1A substrates, when these fluoroquinolones are co-administered. Mechanism based inhibition was also examined in this study. Of the five fluoroquinolones examined, OFX, OBFX and CFX had this inhibition manner. As this inhibition is irreversible, inhibitory effects of the three fluoroquinolones may accumulate, when they are repeatedly administered. Therefore, OFX, OBFX and CFX may result in substantial drug-drug interaction with a CYP1A substrate even in clinical states. As EFX is metabolized to CFX in the body, it may also have the same possibility.
引用
收藏
页码:553 / 557
页数:5
相关论文
共 19 条
[1]   Drug interactions in oncology [J].
Beijnen, JH ;
Schellens, JHM .
LANCET ONCOLOGY, 2004, 5 (08) :489-496
[2]  
Boothe Dawn Merton, 2002, Vet Ther, V3, P409
[3]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[4]  
BURKE MD, 1977, DRUG METAB DISPOS, V5, P1
[5]   METABOLISM OF THEOPHYLLINE AND ITS INHIBITION BY FLUOROQUINOLONES IN RAT HEPATIC MICROSOMES [J].
DAVIS, JD ;
AARONS, L ;
HOUSTON, JB .
XENOBIOTICA, 1995, 25 (06) :563-573
[6]   Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition [J].
Dresser, GK ;
Spence, JD ;
Bailey, DG .
CLINICAL PHARMACOKINETICS, 2000, 38 (01) :41-57
[7]   The effect of orally administered marbofloxacin on the pharmacokinetics of theophylline [J].
Hirt, RA ;
Teinfalt, M ;
Dederichs, D ;
van den Hoven, R .
JOURNAL OF VETERINARY MEDICINE SERIES A-PHYSIOLOGY PATHOLOGY CLINICAL MEDICINE, 2003, 50 (05) :246-250
[8]   Enzyme and plasma protein induction by multiple oral administrations of phenobarbital at a therapeutic dosage regimen in dogs [J].
Hojo, T ;
Ohno, R ;
Shimoda, M ;
Kokue, E .
JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS, 2002, 25 (02) :121-127
[9]   ENROFLOXACIN THEOPHYLLINE INTERACTION - INFLUENCE OF ENROFLOXACIN ON THEOPHYLLINE STEADY-STATE PHARMACOKINETICS IN THE BEAGLE DOG [J].
INTORRE, L ;
MENGOZZI, G ;
MACCHERONI, M ;
BERTINI, S ;
SOLDANI, G .
JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS, 1995, 18 (05) :352-356
[10]  
Kay-Mugford Patricia A, 2002, Vet Ther, V3, P402